Interest continues to grow in the use of microbes to produce cannabinoids.
Intrexon, an American biotech company listed on the Nasdaq stock exchange, has announced a development in its microbial platform capable of producing cannabinoids for medical use.
It has created a yeast strain capable of producing low-cost, robust and consistent cannabinoid outputs through fermentation.
Exectuve directive Chris Savile said: “Microbial fermentation routes to produce cannabinoids provide advantages over traditional plant-based extraction. We expect to optimise strains to produce specific cannabinoids that may be commercialised in the coming years.”


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us